Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00148070 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer
A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT00148070 is a Phase 2 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 45 participants.
The verdict
NCT00148070, a Phase 2 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
This is a research study which aims to improve the way that doctors determine the dose of chemotherapy given to patients. Right now, chemotherapy is determined by a patient's height and weight. However, some patients metabolize chemotherapy faster or slower than the average person because of a different level of drug metabolizing enzyme in the liver. Therefore, some patients are either given too small or too large a dose of chemotherapy because the amount of enzyme is not taken into account. This research study will examine the use of a simple test, call the Erythromycin Breath Test(ERMBT) to determine the amount of enzyme which can metabolize the chemotherapy drug docetaxel (Taxotere). The dose of docetaxel will be tailored to the amount of enzyme which is available to metabolize the drug for each patient.
Interventions
- DRUG Docetaxel
- PROCEDURE Erythromycin Breath Test (ERMBT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 1999-03 |
| Est. Completion | 2006-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00148070
The ClinicalTrials.gov registry entry for NCT00148070 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT00148070 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00148070 about?
NCT00148070 is a clinical study titled "Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer". This is a research study which aims to improve the way that doctors determine the dose of chemotherapy given to patients. Right now, chemotherapy is determined by a patient's height and weight. However, some patients metabolize chemotherapy faster or slower than the average person because of a diffe...
What is the current status of trial NCT00148070?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 1999-03. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00148070?
The interventions under investigation include: Docetaxel (DRUG), Erythromycin Breath Test (ERMBT) (PROCEDURE).
Who is sponsoring clinical trial NCT00148070?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.